However, unlike in the case of Poly(I:C), when Nexavant is administered, there is enhanced secretion of cytokines, such as IFN-β and IL-6, which may induce a unique tumor microenvironment for improved anti-cancer effect. The gene discussed is IFNB1; the disease is cancer.